TITLE

Antibiotic bill doesn't GAIN enough ground

AUTHOR(S)
Ambrose, Paul G.
PUB. DATE
July 2011
SOURCE
Nature Medicine;Jul2011, Vol. 17 Issue 7, p772
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
With an eye to tackling the growing problem of antimicrobial drug resistance, US lawmakers last month proposed new incentives to jump-start the ailing antibiotic industry. but the legislation as written is not likely to have the intended consequences, as it fails to adequately shield companies from competition with generic drugs. To truly entice investment and research from the drug industry, the bill needs to simplify the path to regulatory approval, provide greater protection from generic competition and aid drug companies with intellectual property extensions, tax relief and guaranteed market commitments.
ACCESSION #
62324463

 

Related Articles

  • ESSAY: HATCH-WAXMANIZING COPYRIGHT. Shur-Ofry, Michal // Michigan Telecommunications & Technology Law Review;Fall2011, Vol. 18 Issue 1, p171 

    This Essay presents a novel proposal for counter balancing "copyright overspills." In the background of the discussion is the common reality of users succumbing to rights holders' attempts to license uses which are most likely fair uses or completely free of copyright protection. These practices...

  • Under Review.  // Pharmaceutical Executive;May2002, Vol. 22 Issue 5, p142 

    Highlights several issues critical to the pharmaceutical industry that need to be addressed. Need to balance companies' intellectual property rights with patients' right to access lower-priced generics; Pharmacovigilance and fast-track registration; Biotechnology issues.

  • Generic industry sets goal: clearing biotech approvals. Fredemck, Jim // Drug Store News;4/23/2007, Vol. 29 Issue 6, p28 

    The article highlights the Generic Pharmaceutical Association's 2007 Annual Meeting in Phoenix, Arizona. Health care advocates, generic industry experts and members of Congress voiced support for the Access to Life-Saving Medicine Act, a legislation that would require to create an abbreviated...

  • Generic Pharmaceuticals: IP's Fiercest Litigation Arena. Andersen, Steven // Corporate Legal Times;Nov2003, Vol. 13 Issue 144, p28 

    Focuses on the complications in the generic drug application for patent rights by pharmaceutical companies in the U.S. Employment of strategy to extend the patent life of their products; Impact of the emergence of generic drugs on the pharmaceutical companies; Overview of the process of the...

  • The Eleventh Circuit Holds that Agreements in which Pharamceutical Companies Pay Generic Companies Not to Compete May be Valid. Garrigues, Amy // Journal of Law, Medicine & Ethics;Spring2004, Vol. 32 Issue 1, p181 

    Reports on the decision of the United States Court of Appeals for the Eleventh Circuit on the non-competition agreements of pharmaceutical and generic companies. Effect on the exclusionary right of patent; Confirmation of the exclusivity of the agreement; Provision of balance on the competing...

  • Patent Challenges. J. W. // Pharmaceutical Executive;Jun2007, Vol. 27 Issue 6, p24 

    The article reports that Thailand Government and other third-world nations are challenging patents on critical therapies, a tactic that is stepping up into a serious international confrontation over intellectual property protection. Thailand has been trying to override drug patents on AIDS...

  • Dynamics of India's Life Sciences Outsourcing Industry. Bhatt, Nailesh A. // Pharmaceutical Technology;Aug2007 Supplement, Vol. 31, p65 

    The tightening of intellectual property rights in India under GATT/TRIPS was a crucial inflection point for pharmaceutical outsourcing in India. With that move, pharmaceutical outsourcing to that country has evolved from limited partnering options based mainly on generic drugs and limited pure...

  • Ethical Pharma Companies Fight Generics Head On. Scott, Alex // Chemical Week;7/5/2006, Vol. 168 Issue 23, p22 

    This article reveals that some ethical pharmaceutical companies have started to challenge the established pricing model for branded pharmaceuticals that go off patent. Merck and Pfizer have each opted to offer major price discounts on leading drugs that recently went off patent, to fight...

  • Litigation Is The Business Model For Generic Drug Maker. Andersen, Steven // Corporate Legal Times;Apr2003, Vol. 13 Issue 137, p24 

    Presents a discussion on the litigation challenges faced by Teva Pharmaceutical Industries Limited, manufacturer of generic drugs, in the U.S. Difficulty of handling international intellectual property function; Description of patents held; Competition with brand name pharmaceutical companies. ...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics